Enicepatide: Roche's CT-388 Hits 22.5% at ADA 2026 Roche's enicepatide (CT-388) hit 22.5% placebo-adjusted weight loss at ADA 2026
We'll go through what sits on the relevant prohibited list and whether there's a protocol that fits your situation, or whether the honest answer is to wait until you're out of competition
Thats why we are trusting- Andrew Huberman, Ph.D., a renowned neuroscientist, known for his dedication to science-backed health optimisation
Tesamorelin, a synthetic analogue of growth hormone-releasing hormone (GHRH), activates GHRH receptors within the anterior pituitary, while Ipamorelin selectively activates the ghrelin (GHS-R1a) receptor
Sugary and Alcoholic Drinks Soda, lemonade, punch, and sweet tea: Sugary drinks can add a lot of excess sugar and calories without much satiety, which makes them a poor fit when appetite is already reduced on GLP-1 medication